Earnings Preview: Regeneron (REGN) Q4 Earnings Expected to Decline
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
US FDA approves Dupixent to treat younger kids with esophageal condition
The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to treat an allergic inflammation of the esophagus in children aged one to 11 years old and weighing at least 15 kg...
Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US
The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled m...
Regeneron (REGN) Is Up 3.97% in One Week: What You Should Know
Does Regeneron (REGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
AI is the big thing right now, but the real tool is genetics, says Regeneron CEO Dr. Schleifer
Regeneron CEO Dr. Leonard Schleifer joins 'Mad Money' host Jim Cramer to talk cancer treatments, quarterly earnings, weight loss medication and more.
Regeneron CEO: We want to retain efficacy and eliminate bad side effects with our cancer treatments
Regeneron CEO Dr. Leonard Schleifer joins 'Mad Money' host Jim Cramer to talk cancer treatments, quarterly earnings, weight loss medication and more.
Regeneron CEO says the next big thing for biotech isn't AI, it's gene therapy
Regeneron CEO Leonard Schleifer detailed the biotech company's newest ventures in the pharmaceutical industry.
Regeneron (REGN) Down as Q4 Eylea Preliminary Sales Disappoint
Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea.
Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript)
Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript)
Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade)
Regeneron Pharmaceuticals, Inc.'s shares have risen over 25% in recent months, reaching over $910 per share - a premium explained partly by share buybacks. The company's market cap is around $100 b...
Regeneron hints at 4Q US sales of Eylea below expectations
Regeneron Pharmaceuticals (NASDAQ:REGN) shares fell over 3% in early Monday afternoon trading after it told investors that US net product sales of its franchise of Eylea totalled about $1.46 billio...
Regeneron reports preliminary Q4 U.S. sales of Eylea at $1.34 bln
Regeneron Pharmaceuticals said on Monday its franchise of eye drug Eylea recorded preliminary sales of $1.34 billion in the United States in the fourth quarter.
Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024
TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2023 financial and operating r...
Earnings Estimates Moving Higher for Regeneron (REGN): Time to Buy?
Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Regeneron (REGN) Surges 3.0%: Is This an Indication of Further Gains?
Regeneron (REGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase ...
Related Companies